New Delhi: India has cleared the way for a new diabetes treatment option with the approval of Ozempic (semaglutide injection) by the Central Drugs Standard Control Organization (CDSCO). The decision, announced on September 26, authorises the drug to be prescribed as an add-on therapy for adults with Type 2 diabetes, alongside diet and exercise. Ozempic comes from GLP-1 receptor agonists, a class of medication that helps lower blood sugar while boosting glycemic control. The injection is available in 0.25mg, 0.5mg, and 1mg doses. Patients usually report moderate weight loss as a result of the injection; however, the drug is approved for obesity treatment and diabetes management.

Novo Nordisk, which already markets Rybelsus (oral semaglutide) and Wegovy for obesity, is strengthening its po

See Full Page